Jeffrey Craft
Radiation Oncology · Saint Louis, MONPI 1497936231
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 257 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 46 manufacturers, the largest accounting for just 9.1% — the pattern of someone who eats at a lot of different presentations.
Across 257 payments — averaging $21.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$495
- Novartis$473
- Regeneron Healthcare Solutions, Inc.$450
- AstraZeneca$351
- GT Medical Technologies, Inc$325
- Novocure Inc.$310
- plus $3K from 40 others
Across 13 payments — averaging $1494.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novocure Inc.$19K
What the payments were for
- Food & beverage$5,458100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GammaTile$162
- PTS250$117
- CyberKnife System$114
How this compares
$5,458 in reported general payments places this provider in the 80th percentile of 123 radiation oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sucralfate | 11 | $1,111 |
| Tamsulosin Hcl | 128 | $577 |
| Lidocaine Hcl ViscousLidocaine Hcl | 24 | $485 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $336 |
| Dexamethasone | 27 | $249 |
| Ondansetron OdtOndansetron | 12 | $245 |
| Nystatin | 12 | $202 |
| Silver Sulfadiazine | 13 | $164 |
| Lorazepam | 12 | $21 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Saint Louis
- Clifford RobinsonSaint Louis$817K
- Pamela SamsonSaint Louis$95K
- Jeffrey BradleySaint Louis$75K
- Matthew SprakerSaint Louis$61K
- Lauren HenkeSaint Louis$45K
- Jeff MichalskiSaint Louis$44K
- Stephanie PerkinsSaint Louis$16K
- Hiram GaySaint Louis$12K
- Shahed BadiyanSaint Louis$6K
- Robert FrazierSaint Louis$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.